・The FDA previously rejected approval for RP1 in July. ・The agency noted that the members of the team who reviewed the resubmission were different from those who reviewed the initial application to ...

Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Its product candidates ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...